KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Other Non-Current Liabilities (2016 - 2025)

Eli Lilly (LLY) has disclosed Other Non-Current Liabilities for 17 consecutive years, with $5.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 68.87% year-over-year to $5.9 billion, compared with a TTM value of $5.9 billion through Dec 2025, up 68.87%, and an annual FY2025 reading of $5.9 billion, up 68.87% over the prior year.
  • Other Non-Current Liabilities was $5.9 billion for Q4 2025 at Eli Lilly, up from $3.8 billion in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $5.9 billion in Q4 2025 and bottomed at $1.6 billion in Q4 2021.
  • Average Other Non-Current Liabilities over 5 years is $3.3 billion, with a median of $3.5 billion recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities crashed 56.25% in 2022, then skyrocketed 136.5% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $1.6 billion in 2021, then grew by 10.93% to $1.8 billion in 2022, then grew by 22.84% to $2.2 billion in 2023, then skyrocketed by 55.27% to $3.5 billion in 2024, then soared by 68.87% to $5.9 billion in 2025.
  • Business Quant data shows Other Non-Current Liabilities for LLY at $5.9 billion in Q4 2025, $3.8 billion in Q3 2025, and $5.7 billion in Q2 2025.